HomeClinical ResearchCurrent Clinical Trails A Phase I/II Open-Label, Safety And Preliminary Efficacy Study Of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors (NSCLC, RCC, Bladder, Breast triple negative)
MRx0518-I-002
Condition: Histological or cytological evidence of advanced and/or metastatic or recurrent NSCLC, renal cell carcinoma, bladder cancer, Head and Neck, Triple Negative | Last Updated: | Status: